| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 19.8K | 55.5% |
| Total Income | 19.8K | 55.5% |
| Expenditure | 10.9K | 18.1% |
| PBT | 8.8K | 156.1% |
| Net Profit | 7.4K | 168.0% |
| OPM | — | |
| NPM | 37.35% | 15.68pp |
| EPS | 8.27 | 169.4% |
Eli Lilly Reports Q1 2026 Revenue Up 56% to $19.8 Billion
03 May 2026 · 3 May, 6:03 pm
Summary
Eli Lilly and Company reported a strong start to 2026, with Q1 revenue increasing by 56% to $19.8 billion. This growth was primarily driven by volume increases, although partially offset by lower realized prices. The company's EPS also saw significant growth, with a 170% increase on a reported basis. Due to the strong Q1 performance, Lilly raised its full-year revenue guidance to a range of $82.0 billion to $85.0 billion.
Key Highlights
- 1
Eli Lilly's revenue in Q1 2026 increased by 56% to $19.8 billion, primarily driven by volume growth.
- 2
Q1 2026 EPS increased by 170% to $8.26 on a reported basis and increased by 156% to $8.55 on a non-GAAP basis.
- 3
The company increased its 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion.
- 4
Mounjaro revenue increased 125% to $8.7 billion worldwide in Q1 2026.
- 5
U.S. Zepbound revenue increased 79% to $4.1 billion in Q1 2026.
- 6
The U.S. FDA approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.
Management Comments
David A. Ricks
"2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion," said David A. Ricks, Lilly chair and CEO. “A key milestone was the U.S. FDA approval of Foundayo—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s. We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions.”
Informational and educational content only. Not investment advice.